{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:02:51Z","timestamp":1790402571537,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clml.2015.02.008","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T16:11:14Z","timestamp":1439914274000},"page":"S64-S69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S","title":["Practical Management of Lenalidomide-Related Rash"],"prefix":"10.1016","volume":"15","author":[{"given":"Sara M.","family":"Tinsley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Kurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean A.","family":"Ridgeway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.008_bib1","series-title":"Revlimid (lenalidomide) [prescribing information]","year":"2014"},{"key":"10.1016\/j.clml.2015.02.008_bib2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.008_bib3","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.008_bib4","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.008_bib5","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A\u00a0randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.008_bib6","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with\u00a0mantle-cell lymphoma who relapsed or progressed after or were refractory to\u00a0bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.008_bib7","first-page":"358","article-title":"Update on safety and long-term outcomes in lenalidomide (LEN)-treated patients with red blood cell (RBC) transfusion-dependent low-\/int-1-risk myelodysplastic syndromes (MDS) and del(5q) (abstract 0870)","volume":"97","author":"Hellstrom-Lindberg","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.02.008_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.clml.2013.03.006","article-title":"Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis","volume":"13","author":"Nardone","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2015.02.008_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2975.2975","article-title":"Real-world analysis of Celgene Global Drug Safety database: early permanent discontinuation of lenalidomide (LEN) in patients with myelodysplastic syndromes (MDS) due to nonserious rash (abstract 2975)","volume":"122","author":"Weiss","year":"2013","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2015.02.008_bib10","first-page":"7","article-title":"Current approaches to the diagnosis and management of myelodysplastic syndromes","volume":"2","author":"Kurtin","year":"2011","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.clml.2015.02.008_bib11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2125.2010.03703.x","article-title":"Skin manifestations of drug allergy","volume":"71","author":"Ardern-Jones","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2015.02.008_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2007.01.011","article-title":"Recognition and management of severe cutaneous drug reactions","volume":"25","author":"Knowles","year":"2007","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clml.2015.02.008_bib13","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1365-2133.2003.05584.x","article-title":"A\u00a06-month prospective survey of\u00a0cutaneous drug reactions in a hospital setting","volume":"149","author":"Fiszenson-Albala","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2015.02.008_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0031-6997(24)01501-1","article-title":"Cutaneous drug reactions","volume":"53","author":"Svensson","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clml.2015.02.008_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anai.2010.08.002","article-title":"Drug allergy: an updated practice parameter","volume":"105","author":"Joint Task Force on Practice Parameters","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clml.2015.02.008_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1586\/edm.11.28","article-title":"Drug eruptions in dermatology","volume":"6","author":"Al-Niaimi","year":"2011","journal-title":"Expert Rev Dermatol"},{"key":"10.1016\/j.clml.2015.02.008_bib17","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/archderm.142.10.1298","article-title":"Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma","volume":"142","author":"Sviggum","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2015.02.008_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/13543784.15.2.171","article-title":"Current therapeutic uses of lenalidomide in multiple myeloma","volume":"15","author":"Hideshima","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2015.02.008_bib19","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-10-0421","article-title":"Histopathologic and immunohistochemical\u00a0characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1\/2 inhibitors in cancer patients","volume":"16","author":"Nardone","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.02.008_bib20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2015.02.008_bib21","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ajh.21004","article-title":"Successful desensitization in a patient with lenalidomide hypersensitivity","volume":"82","author":"Phillips","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.02.008_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clml.2012.09.003","article-title":"Desensitization to lenalidomide in a patient with relapsed multiple myeloma","volume":"13","author":"Seki","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2015.02.008_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","article-title":"A\u00a0proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2015.02.008_bib24","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Available at:\u00a0http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed October 28,\u00a02014."},{"key":"10.1016\/j.clml.2015.02.008_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00277-008-0449-0","article-title":"Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes","volume":"87","author":"Giagounidis","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.02.008_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CAD.0000000000000032","article-title":"Life-threatening dermatologic adverse events in oncology","volume":"25","author":"Rosen","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clml.2015.02.008_bib27","series-title":"Revlimid (lenalidomide) [summary of product characteristics]","year":"2014"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T01:42:35Z","timestamp":1748569355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015000373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":27,"alternative-id":["S2152265015000373"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Management of Lenalidomide-Related Rash","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}